Yellamraju Kumar, MD
Internal Medicine · Alden, NYNPI 1326004649
Payments from drug & device makers
Across 186 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$378
- GSK$254
- Astellas Pharma US Inc$217
- Lilly USA, LLC$144
- Pfizer$133
- plus $797 from 17 others
What the payments were for
- Food & beverage$3,04595%
- Education$1605%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 98 | $1,281 |
| AstraZeneca | 17 | $378 |
| GSK | 12 | $254 |
| Astellas Pharma US Inc | 4 | $217 |
| Lilly USA, LLC | 8 | $144 |
| Pfizer | 6 | $133 |
| Amgen | 6 | $108 |
| AbbVie(2 entities) | 6 | $97 |
| Sanofi-aventis U.S. LLC | 5 | $73 |
| Bayer | 3 | $70 |
| Abbott | 3 | $69 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Dexcom, Inc. | 1 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Medtronic | 1 | $33 |
| Exact Sciences | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Eisai Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$115
How this compares
$3,205 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $316,004 |
| OzempicSemaglutide | 271 | $289,029 |
| JardianceEmpagliflozin | 106 | $103,065 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $95,878 |
| XareltoRivaroxaban | 88 | $90,658 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 56 | $64,582 |
| MounjaroTirzepatide | 41 | $61,068 |
| FarxigaDapagliflozin Propanediol | 49 | $53,315 |
| MyrbetriqMirabegron | 75 | $42,727 |
| TrulicityDulaglutide | 28 | $39,463 |
| SynjardyEmpagliflozin/Metformin Hcl | 32 | $39,180 |
| EntrestoSacubitril/Valsartan | 29 | $29,772 |
| CreonLipase/Protease/Amylase | 22 | $28,215 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $26,500 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $26,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $133 | $339,227354 claims |
| Novo NordiskOzempic | $1,281 | $289,029271 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat | $35 | $214,437208 claims |
| Lilly USA, LLCMounjaro, Trulicity | $144 | $100,53069 claims |
| Johnson & JohnsonXarelto, Invokana | $11 | $98,494100 claims |
| GSKTrelegy Ellipta | $254 | $95,878105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $378 | $79,81581 claims |
| AbbVieCreon, Linzess, Synthroid | $97 | $51,104196 claims |
| Astellas Pharma US IncMyrbetriq | $217 | $42,72775 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $73 | $26,15833 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $14,978905 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Alden
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.